The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH₄EDTA gradient

References

• DomingoJLDevelopmental toxicity of metal chelating agentsReprod Toxicol19981254995109763241
   PubMed Web of Science ®Google Scholar
• FloraSJPachauriVChelation in metal intoxicationInt J Environ Res Public Health2010772745278820717537
   PubMed Web of Science ®Google Scholar
• GordonGFEDTA and Chelation Therapy: History and Mechanisms of ActionPayson, AZGordon Research Institute2000
   Google Scholar
• RiordanHDCheraskinEDirksMMineral excretion associated with EDTA chelation therapyJournal of Advancement in Medicine199032111123
   Google Scholar
• WatersRSBrydenNAPattersonKYVeillonCAndersonRAEDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zincBiol Trace Elem Res200183320722111794513
   PubMed Web of Science ®Google Scholar
• BornTKontoghiorgheCNSpyrouAKolnagouAKontoghiorghesGJEDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessmentToxicol Mech Methods2013231111722991933
   PubMed Web of Science ®Google Scholar
• ClarkeNEAtherosclerosis, occlusive vascular disease, and EDTAAm J Cardiol19606223323613810514
   PubMed Web of Science ®Google Scholar
• VillarruzMVDansATanFChelation therapy for atherosclerotic cardiovascular disease [review]Cochrane Database Syst Rev20024CD00278512519577
   PubMedGoogle Scholar
• KitchellJRPalmonFJrAytanNMeltzerLEThe treatment of coronary artery disease with disodium EDTA: a reappraisalAm J Cardiol196311450150614033183
   PubMed Web of Science ®Google Scholar
• BlumerWCrantonEMNinety percent reduction in cancer mortality after EDTA chelation therapy with EDTAJournal of Advancement in Medicine198921–2183188
   Google Scholar
• SeelyDMWuPMillsEJEDTA chelation therapy for cardiovascular disease: a systematic reviewBMC Cardiovasc Disord200553216262904
   PubMedGoogle Scholar
• BussJLTortiFMTortiSVThe role of iron chelation in cancer therapyCurr Med Chem200310121021103412678674
   PubMed Web of Science ®Google Scholar
• CrantonEMFrackeltonJPFree oxygen radical pathology and EDTA chelation therapy: mechanisms of actionJournal of Advancement in Medicine1998114277310
   Google Scholar
• HuchoFKoglerHPribillaISchieblerWTripierDInventorsHoechst Aktiengesellschaft, assigneeUse of ethylenediaminetetraacetic acid as inhibitor of calcium/calmoduline-dependent protein kinase II or protein kinase C European patent CA2002637 A11990510
   Google Scholar
• MundyGRGuiseTAHypercalcemia of malignancyAm J Med199710321341459274897
   PubMed Web of Science ®Google Scholar
• BodyJJBone metastases and tumor-induced hypercalcemiaCurr Opin Oncol1992446246311511019
   PubMedGoogle Scholar
• AbdiSAliARole of ROS modified human DNA in the pathogenesis and etiology of cancerCancer Lett199914211910424774
   PubMed Web of Science ®Google Scholar
• Martinez-CayuelaMOxygen free radicals and human diseaseBiochimie19957731471617647106
   PubMed Web of Science ®Google Scholar
• ThompsonKAGoodaleDBThe recent development of propofol (Diprivan®)Intensive Care Med200026Suppl 4S400S40411310902
   PubMedGoogle Scholar
• WeissRBThe anthracyclines: will we ever find a better doxorubicin?Semin Oncol19921966706861462166
   PubMed Web of Science ®Google Scholar
• BasserRLGreenMDStrategies for prevention of anthracycline cardiotoxicityCancer Treat Rev199319157778431927
   PubMed Web of Science ®Google Scholar
• DudkaJBurdanFKorgaAIntensification of doxorubicin-related oxidative stress in the heart by hypothyroidism is not related to the expression of cytochrome P450 NADPH-reductase and inducible nitric oxide synthase, as well as activity of xanthine oxidaseOxid Med Cell Longev2012201213932722966413
   PubMed Web of Science ®Google Scholar
• Tokarska-SchlattnerMZauggMZuppingerCWallimannTSchlattnerUNew insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energeticsJ Mol Cell Cardiol200641338940516879835
   PubMed Web of Science ®Google Scholar
• OrtegaRDevesGBohicSSimionoviciAMénezBBonnin-MosbahMIron distribution in cancer cells following doxorubicin exposure using proton and X-ray synchrotron radiation microprobesNucl Instrum Methods Phys Res B20011811480484
   Google Scholar
• OctaviaYTocchettiCGGabrielsonKLJanssensSCrijnsHJMoensALDoxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategiesJ Mol Cell Cardiol20125261213122522465037
   PubMed Web of Science ®Google Scholar
• ChenYWanYWangYZhangHJiaoZAnticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticlesInt J Nanomedicine201162321232622072869
   PubMed Web of Science ®Google Scholar
• DudkaJGierobaRKorgaADifferent effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicityEvid Based Complement Alternat Med2012201260618323258992
   PubMed Web of Science ®Google Scholar
• HrubyMKonakCUlbrichKPolymeric micellar pH-sensitive drug delivery system for doxorubicinJ Control Release2005103113714815710507
   PubMed Web of Science ®Google Scholar
• MitraSGaurUGhoshPMaitraATumour targeted delivery of encapsulated dextran–doxorubicin conjugate using chitosan nanoparticles as carrierJ Control Release2001741–331732311489513
   PubMed Web of Science ®Google Scholar
• GabizonAMartinFPolyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumorsDrugs199754Suppl 415219361957
   PubMed Web of Science ®Google Scholar
• GubernatorJChwastekGKorycinskaMThe encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivoJ Control Release20101461687520510316
   PubMed Web of Science ®Google Scholar
• YangYMaYWangSA novel method to load topotecan into liposomes driven by a transmembrane NH4EDTA gradientEur J Pharm Biopharm201280233233922041601
   PubMed Web of Science ®Google Scholar
• CuiJLiCGuoWDirect comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?J Control Release2007118220421517239468
   PubMed Web of Science ®Google Scholar
• LiXHirshDJCabral-LillyDDoxorubicin physical state in solution and inside liposomes loaded via a pH gradientBiochim Biophys Acta19981415123409858673
   PubMed Web of Science ®Google Scholar
• HaranGCohenRBarLKBarenholzYTransmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak basesBiochim Biophys Acta1993115122012158373796
   PubMed Web of Science ®Google Scholar
• FritzeAHensFKimpflerASchubertRPeschka-SüssRRemote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradientBiochim Biophys Acta20061758101633164016887094
   PubMed Web of Science ®Google Scholar
• MeiLDeckerEAMcClementsDJEvidence of iron association with emulsion droplets and its impact on lipid oxidationJ Agric Food Chem1998461250725077
   Web of Science ®Google Scholar
• MatalonSTOrnoyALishnerMReview of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta)Reprod Toxicol200418221923015019720
   PubMed Web of Science ®Google Scholar
• MinottiGRecalcatiSMennaPSalvatorelliECornaGCairoGDoxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanismsMethods Enzymol200437834036115038979
   PubMed Web of Science ®Google Scholar
• DugiDTakemotoAThe role of heavy metal detoxification in heart disease and cancers: a pilot study in detoxification of heavy metalsPaper presented at: WESCON Biomedicine and Bioengineering ConferenceSeptember 24, 2002Anaheim, CA, USA
   Google Scholar